Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070698 | 0.88 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL8032770 | 0.86 | ADORA2A (0.82) | ADORA2AADORA1 | |
| SCHEMBL12034929 | 0.82 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL1378743 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL1831234 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL8037347 | 0.80 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL8069784 | 0.80 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL12034919 | 0.79 | ADORA2A (0.86) | ADORA2AADORA1 | |
| SCHEMBL12034952 | 0.79 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL8029365 | 0.79 | ADORA2A (0.84) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312956-A1 | ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312956-A1 | ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | US | disclosed |
| WO-2011159302-A1 | ARYLINDENOPYRIMIDINES FOR TREATING NEURODEGENERATIVE AND MOVEMENT DISORDERS WHILE MINIMIZING CARDIAC TOXICITY | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| EP-2220053-B1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-11 | — | — | EP | disclosed |
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055548-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111804-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885 |
| US-20110312956-A1 | ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING | ADORA2A, ADORA1, P2RX5 | ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.